Foundation
The Khavinson Lineage
Six decades of biochemical and clinical work establishing short-peptide bioregulation as a distinct pharmacological category. The institutional research program that characterized the privileged subclass.
Read →Research
Four decades of empirical foundation.
The institutional research program, the cross-species evidence, the peer-reviewed literature, and the patent portfolio that anchors the discipline.
In This Section
Four bodies of evidence.
Mammalian Evidence
Cross-Species Evidence
In-vivo demonstration of bioregulator activity across mouse, rat, rabbit, dog, primate, and bovine models. The cross-species consistency that supports translation to clinical use.
Read →Peer Review
Published Literature
The body of peer-reviewed research from institutional laboratories across Russia, Ukraine, Italy, South Korea, and the United Kingdom. Bibliographic anchors for the discipline.
Read →Intellectual Property
Patent Portfolio Overview
The patent-pending portfolio covering proprietary trade-named bioregulator portfolio u2014 Telogenixu2122, Thymogenixu2122, Vasogenixu2122, Dermogenixu2122, Cortigenixu2122, Lymphogenixu2122, and Gonadogenixu2122 u2014 patent-pending across compositions, methods of use, formulations, and combinations.
Read →